CanSino Biologics Inc.
Research CanSino Biologics Inc. (6185.HK) on Bullrun: market cap HKD 7.49B, P/E 168.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6185.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 7.49B
- P/E168.4
- Financial periodFY2025
- RevenueCNY 1.06B
- Revenue growth28.4%
- Net incomeCNY 27.87M
- Free cash flow-CNY 166.04M
- Gross margin75.4%
Valuation Snapshot
latest market cap is HKD 7.49B; P/E is 168.4.
Peer valuation comparison
Latest P/E is 168.44x versus a Healthcare sector median of 21.69x (676.5% above).
Latest P/E is 168.44x versus a China median of 16.26x (935.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.06B | CNY 27.87M | -CNY 166.04M | 75.4% | 0.11 | CNY 1.22B | CNY 1.29B | CNY 4.95B |
| FY2024 | CNY 824.88M | -CNY 378.88M | -CNY 626.43M | 70.4% | -1.53 | CNY 1.56B | CNY 2.01B | CNY 4.91B |
| FY2023 | CNY 345.18M | -CNY 1.48B | -CNY 1.53B | -253.8% | -6.01 | CNY 2.05B | CNY 2.70B | CNY 5.27B |
| FY2022 | CNY 1.03B | -CNY 909.43M | -CNY 2.96B | -18.1% | -3.68 | CNY 3.39B | CNY 2.70B | CNY 6.75B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 7.49B | 168.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
| Year | Dividends/share |
|---|---|
| FY2022 | 0.94 CNY |
About CanSino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CanSino Biologics Inc.'s market cap?
CanSino Biologics Inc.'s market capitalization is HKD 7.49B.
What is CanSino Biologics Inc.'s P/E ratio?
CanSino Biologics Inc.'s price-to-earnings (P/E) ratio is 168.4.
What does CanSino Biologics Inc. do?
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.